Department of Neurosurgery, Kirikkale University Faculty of Medicine, Kirikkale, Turkey.
Department of Neurology, Kirikkale University Faculty of Medicine, Kirikkale, Turkey.
Neurol Res. 2021 Jun;43(6):482-495. doi: 10.1080/01616412.2020.1870338. Epub 2021 Jan 5.
: In patients with spontaneous intracerebral hematoma (ICH), early-stage hematoma expansion has been associated with poor prognosis in literature. This study aimed to develop predictive parameter(s) as well as a new scale to define hematoma expansion and short-term prognosis in patients with ICH.: In 46 patients with ICH, Glasgow Coma Scale (GCS) scores, non-contrast CT (NCCT) markers (hematoma volume on admission and follow-up, hypodensity, intraventricular hemorrhage, blend and island sign, BAT score), and modified Rankin Scale scores were evaluated for predicting the hematoma expansion risk and mortality risk. Furthermore, a newly developed scale called the 'HEMRICH scale' was constituted using the GCS score, hematoma volumes, and some NCCT markers.: and test results revealed that GCS score, initial hematoma volume value, hypodensity, intraventricular haemorrhage, BAT score, and HEMRICH scale score could be the best markers in predicting hematoma expansion risk whereas GCS score, intraventricular haemorrhage, BAT score, hematoma expansion, and HEMRICH scale score could be the best markers in predicting mortality risk (p = 0.01). Moreover, and test results showed that HEMRICH scale score could predict both hematoma expansion and mortality risks validly (Kaiser-Meyer-Olkin test value = 0.729) and reliably (Cronbach's alpha = 0.564).: It was concluded that the GCS score, intraventricular haemorrhage, and BAT score could predict both hematoma expansion risk and mortality risk in the early stage in patients with ICH. Furthermore, it was suggested that the newly produced HEMRICH scale could be a valid and reliable scale for predicting both hematoma expansion and mortality risk.
自发性脑出血(ICH)患者的早期血肿扩大与文献中的不良预后相关。本研究旨在开发预测参数和新的量表,以定义 ICH 患者的血肿扩大和短期预后。
在 46 例 ICH 患者中,评估了格拉斯哥昏迷量表(GCS)评分、非对比 CT(NCCT)标志物(入院和随访时的血肿体积、低密区、脑室内出血、混合和岛屿征、BAT 评分)和改良 Rankin 量表评分,以预测血肿扩大风险和死亡率风险。此外,使用 GCS 评分、血肿体积和一些 NCCT 标志物组成了一个新开发的量表,称为“HEMRICH 量表”。
和检验结果表明,GCS 评分、初始血肿体积值、低密区、脑室内出血、BAT 评分和 HEMRICH 量表评分可能是预测血肿扩大风险的最佳标志物,而 GCS 评分、脑室内出血、BAT 评分、血肿扩大和 HEMRICH 量表评分可能是预测死亡率风险的最佳标志物(p=0.01)。此外,和检验结果表明,HEMRICH 量表评分可以有效(Kaiser-Meyer-Olkin 检验值=0.729)和可靠(Cronbach's alpha=0.564)预测血肿扩大和死亡率风险。
GCS 评分、脑室内出血和 BAT 评分可预测 ICH 患者早期血肿扩大风险和死亡率风险。此外,建议新产生的 HEMRICH 量表可作为有效且可靠的量表,用于预测血肿扩大和死亡率风险。